Skip to main content
OpenTrials
Completed

NCT Number: NCT07659223

Improving Outcomes for Juvenile Idiopathic Arthritis

Children and parents often experience uncertainty and stress when juvenile idiopathic arthritis (JIA) is first diagnosed, which creates a need for structured support. Juvenile Idiopathic Support Program (JASP-1) provide patient-and family centered support during the first year after diagnosis. However, little is known about how a support program like JASP-1 can influence outcomes. Therefore, this study aimed to longitudinally examine registry data from children who participated in JASP 1 and to compare the outcomes with registry data from a matched control group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Juvenile Idiopahtic Arthritis

Age range

0 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Karolinska University Hospital

Stockholm, 17176, Sweden

About this study

Methods: The study is a longitudinal register study with data from the Swedish Pediatric Rheumatology Quality Register (PedSRQ). Data included outcome measures from the child and/or the parents as well as clinical information's from the physicians.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For the JASP-1: Diagnosed with JIA and have completed the JASP-1.
  • For the control group: Diagnosed with JIA at the same clinic as above

Exclusion criteria

  • No JIA diagnosis
  • Change of diagnose during the year
  • Do not understand or speak Swedish

Treatment and study plan

The intervention was a one year support program JASP-1

Behavioral

Seven structured visits with a patient-and family-centered approach was used in the JASP-1 program, in which children newly diagnosed with JIA and their parents were invited to participate in.

Primary outcomes

  1. CHAQ, Disabkids, Physicians global assessment

    Time frame: For one year following JIA diagnosis

    56 children received JASP-1and was on 3 timepoints compared with 60 children matched in disease, gender and age.The measures compared is CHAQ including pain, disease impact on overall well-being and school attendance, DISABKIDS, JADAS-71, Physicians global assessment, Number of active joints, Number of joint injections and Pharmacological treatment.

    Outcomes at 12 months, were analyzed using the non parametric Mann-Whitney U test. For categorical variables differences were analyzed using the chi-square test to compare proportions. Repeated measurement ANOVA was used for calculating differences over time between the two groups. P value < 0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 31.

  2. CHAQ

    Time frame: Assessed several times during the first year after diagnosis. Values from 0-3

    Childhood Health Assessment Queationnaire

  3. Disabkids

    Time frame: Assessed at 3 timepoints during the first year, values between 0-100

    Health Related Quality of Life

  4. Phycisians global assessment

    Time frame: During the first year after diagnosis

    Assessed at 3 timepoint during the first year after diagnosis. Valued on a VAS scale 0-10

Sponsors and collaborators

Lead sponsor

Region Stockholm

Other Gov

Collaborators

  • Karolinska Institutet
  • Karolinska University Hospital

Registry information

Official study title

Improving Outcomes for Children Newly Diagnosed With Juvenile Idiopathic Arthritis Through a Structured Support Program (JASP-1) - A Longitudinal Register Study

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Jun 22, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.